Corinne Faivre-Finn, Professor of Thoracic Radiation Oncology at The University of Manchester, shared on LinkedIn:
“Delighted to share our latest work on the real-world evaluation of the Christie Symptom Inventory – Lung Cancer (CSI-Lung) ePROM, now published in Lung Cancer.
At The Christie NHS Foundation Trust, we are proud to have implemented ePROMs in the routine clinical setting, using patient-friendly questionnaires adapted from CTCAE items. This study provides a comprehensive evaluation of CSI-Lung using COSMIN methodology and real-world data, looking at validity, reliability, responsiveness and, importantly, patient experience.
Some key findings:
- 2,483 patients with lung cancer contributed routinely collected ePROM data, with a further 274 patients providing feedback on their experience.
- Strong evidence of reliability, validity and responsiveness, with results consistent with clinical expectations.
- Cognitive interviews confirmed that the items were relevant, comprehensible and comprehensive.Most importantly, patients found CSI-Lung highly acceptable:
- 93% found it easy to complete
- 92% considered it clinically useful
- 89% felt it supported their care
These findings support the use of CSI-Lung for routine symptom monitoring in clinical practice and provide an important foundation for wider adoption of ePROMs in routine cancer care.
Huge thank you to our 2 outstanding early career reseachers who led this work – Thitikorn Nuamek and Kuan Liao, Ashleigh Ward , Ramsay Lochhead Devaraj, James Price, Katie Noon, Sally Taylor and Janelle Yorke, and to all the patients and colleagues who contributed to this work.”
Title: Real-world evaluation of the christie symptom inventory-lung cancer (CSI-lung) electronic patient-reported outcome measure: validity, reliability, responsiveness, and patient experiences
Authors: Thitikorn Nuameka, Kuan Liaob, Ashleigh Ward, Ramsay Lochhead Devaraj, James Price, Katie Noon, Sally Taylor, Corinne Faivre-Finn, Janelle Yorke.
Read the full article.
This also can be interesting:
Targeted Therapy Resistance in NSCLC: Critical Next Steps
